Statement of Changes in Beneficial Ownership (4)
29 8월 2019 - 5:31AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DUGAN RICHARD W |
2. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc.
[
VNDA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
298 BEACON CIRCLE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/26/2019
|
(Street)
BOALSBURG, PA 16827
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
8/26/2019
|
|
M
|
|
15000
|
A
|
$14.78
|
50770
|
D
|
|
Common Stock
|
8/26/2019
|
|
S(1)
|
|
15000
|
D
|
$14.85
|
35770
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Nonstatutory Stock Option (Right to Buy)
|
$14.78
|
8/26/2019
|
|
M
|
|
|
15000
|
(2)
|
8/26/2019
|
Common Stock
|
15000
|
$0.00
|
0
|
D
|
|
Explanation of Responses:
|
(1)
|
Represents shares of common stock sold to cover the payment of the option exercise price (which represents 99.94% of the proceeds from the sales made by the Reporting Person) of the option, which was set to expire on August 26, 2019.
|
(2)
|
The option vested in 12 equal monthly installments beginning on September 27, 2009.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
DUGAN RICHARD W 298 BEACON CIRCLE BOALSBURG, PA 16827
|
X
|
|
|
|
Signatures
|
/s/ Richard W. Dugan
|
|
8/28/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex 0년 1월 7일, 2024 (2 주 전) • PR Newswire (US) |
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders 0년 20월 6일, 2024 (4 주 전) • PR Newswire (US) |
Form 8-K - Current report 0년 14월 6일, 2024 (1 월 전) • Edgar (US Regulatory) |
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak 0년 13월 6일, 2024 (1 월 전) • PR Newswire (US) |
Form 8-K - Current report 0년 7월 6일, 2024 (1 월 전) • Edgar (US Regulatory) |
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. 0년 6월 6일, 2024 (1 월 전) • PR Newswire (US) |
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference 0년 31월 5일, 2024 (2 월 전) • PR Newswire (US) |
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY® 0년 31월 5일, 2024 (2 월 전) • PR Newswire (US) |
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 0년 30월 5일, 2024 (2 월 전) • PR Newswire (US) |
Form 8-K - Current report 0년 25월 5일, 2024 (2 월 전) • Edgar (US Regulatory) |
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders 0년 25월 5일, 2024 (2 월 전) • PR Newswire (US) |
Form 4 - Statement of changes in beneficial ownership of securities 0년 25월 5일, 2024 (2 월 전) • Edgar (US Regulatory) |
More Vanda Pharmaceuticals Inc. News Articles
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.